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Abstract 
Hypergranulation (or overgranulation) is an excess of granulation tissue beyond the 
amount required to replace the tissue deficit incurred as a result of skin injury or 
wounding. An infrequent but not rare consequence of wounding, the dearth of 
reliable evidence on the subject of hypergranulation has led to widely varying 
practices over time, including some which cause pain or discomfort and some 
which may further impair healing. However, despite a relatively poor evidence base, 
it is possible to ascertain that clinicians recognise different types of 
hypergranulation tissue in practice and that a variety of factors contribute to their 
development. Coupled with an understanding of normal healing processes, this 
differentiation of types and identification of contributory factors goes some way 
toward identifying effective treatment pathways and justifying treatment decisions, 
one of which includes adopting a wait and see approach.  
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 Limited understanding of aetiology  
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 ‘Wait and see’ is a viable option 
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Introduction 
Hypergranulation tissue is an excess of granulation tissue beyond the amount 
required to replace the tissue deficit incurred as a result of skin injury or wounding  
Most wound care practitioners will see it at some point in their practice, some more 
frequently than others, however, the absence of published best practice guidance 
for managing hypergranulation tissue may lead practitioners to use out-dated or 
harmful practices to resolve the problem. The purpose of this article is to identify 
what is currently known about hypergranulation and offer guidance on how to make 
the best use of this knowledge to support clinical practice. 
 
Healing in the proliferative phase 
Hypergranulation forms in the proliferative phase of healing; in wounds healing by 
secondary intention this phase is characterised by the formation of granulation 
tissue and epithelial tissue. Granulation tissue is the wound filler, used to restore 
the tissue deficit caused by wounding (Tortora and Grabowski, 2000). It grows from 
the base of the wound until it comes level to the surface of the surrounding skin. 
When it has, epithelial cells at the wound margins and from around the base of any 
remnant hair follicles in the wound, start to divide and multiply, moving across the 
surface of the wound to re-establish skin integrity (Flanagan, 2000; Waugh and 
Grant, 2001). This re-epithelialisation of the wound can only occur when the wound 
defect has been restored sufficiently to bring it level to the surrounding skin 
(Dowsett, 2002). 
 
Tissue types 
Healthy granulation tissue presents as a highly vascular, moist, pinkish/red tissue  
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with an undulating (granular) surface; it is characterised by a dense network of 
capillaries, high numbers of fibroblasts and macrophages and newly formed 
collagen fibres (Vuolo, 2009). Epithelial tissue is seen as a delicate pinkish/white 
skin tissue (Flanagan, 2000) which provides coverage over the newly formed 
granulation tissue. It is characterised by layers of closely packed cells (stratified 
epithelium) (Martin, 1997); although fragile in the early stages of healing these 
layers eventually mature to form a robust protective exterior to the skin.   
 
Hypergranulation  
In some wounds, production of granulation tissue continues beyond the height of 
the wound surface resulting in a raised mass (or peduncle) in excess of the wound 
itself. This tissue, known as hypergranulation tissue, can impede healing in several 
ways. It may prevent the migration of epithelial cells across the wound surface i.e. 
these cells do not travel vertically, and increase the risk of infection i.e. the longer 
the wound is open the higher the risk of infection (Nelsen, 1999), particularly if the 
exuberant tissue is moist and highly vascular, as is often the case. It has also been 
suggested that hypergranulation tissue may increase the risk of scar formation by 
forcing the wound edges further apart (Dunford, 1999).  
 
Characteristics of hypergranulation 
Hypergranulation is known by many terms including overgranulation, proud flesh, 
hypertrophic granulation and hyperplasia of granulation tissue (Harris and Rolstad, 
1994; Young, 1995). It is an aberrant healing response, presenting as an 
overgrowth of fibroblasts and endothelial cells with a similar structure to healthy 
granulation tissue (Dunford, 1999, Semchyshyn, 2009) but in excess of the norm.  
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Hypergranulation occurs in a wide range of wounds including pressure ulcers, 
burns and venous ulcers and presents clinically in several forms. Commonly, it is 
seen as a spongy, friable, exuberant mass of tissue; sometimes beefy red, 
sometimes almost purple in colour (Harris and Rolstad, 1994; Johnson, 2007). 
Unhealthy in appearance, this kind of hypergranulation tissue is often associated 
with wound infection (Johnson, 2007) in which case there may be high exudate 
levels with associated maceration. It may also bleed readily. Alternatively, ‘healthy’ 
hypergranulation tissue is characterised by an overgrowth of red-pink , moist tissue, 
which may bleed but not readily; it is otherwise symptom-free (see 
Hypergranulation - clinical presentation Box 1). In any form, hypergranulation does 
not appear to cause the patient discomfort or pain.  
 
Cause 
Relatively little is known about the cause of hypergranulation. It is not a rare 
phenomenon; most wound care clinicians will have seen cases, some quite 
regularly. It may also be that some cases go undiagnosed due to clinical 
inexperience. The (apparently) low prevalence makes it difficult to investigate in 
sufficient numbers (Nelson, 1999) and, although it can delay healing, it is much 
further down the list of research priorities than many other wound-related problems.  
 
Suggested causes include prolonged inflammation caused by infection or foreign 
body irritant (such as dressing fibres) (Wood, 1976; Zitelli, 1984; Stone, 1986; 
Harris and Rolstad, 1994; Nelsen, 1999) or by external friction (Hanlon and 
Heximer, 1994). This latter cause has been postulated in relation to gastrostomy 
tubes and supra-pubic catheter sites where the constant rubbing of the tube against 
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the skin may cause an inflammatory response. If this is the case, then any similar 
irritation to the wound bed for example through dressing contact or through 
repeated patient contact could have a similar effect. Inflammation may also be 
caused by an allergic reaction e.g. to the dressing or adhesive backing. The result 
of prolonged inflammation, whatever the cause, may be a stimulation of ground 
substance formation (Dunford, 1999) in excess of what is required for wound 
healing.  
 
Links between the use of occlusive dressings (such as hydrocolloids) and 
hypergranulation have also been made (Falanga, 1988). The enhanced effect of 
growth factors under occlusive dressings (Bolton et al, 1991; Harris and Rolstad, 
1994), the accumulation of fluid beneath the dressing resulting in tissue oedema 
(Vandeputte and Hoekstra, undated) and the possibility that occlusivity induces 
cytoxic effects (Van Luyn et al, 1992) have all been cited as possible connections.  
 
There may also be a relationship between matrix metalloproteinases (MMPs) and 
the development of hypergranulation. MMPs are a group of proteolytic (protein 
degrading) enzymes which play an important role in the proliferative phase of 
healing (Stephens and Thomas, 2002). In particular, collagenese regulates the 
balance between collagen synthesis and lysis by facilitating the growth of new 
connective tissue and the re-absorption of the extra cellular matrix (ECM), the 
temporary filler which physically supports the newly formed blood vessels and 
granulation tissue characteristic of the proliferative phase (Edwards al., 1987; 
Stephens and Thomas, 2002). Sussman and Bates-Jensen (2007) suggest an 
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imbalance of collagen synthesis and lysis could result in the unchecked proliferation 
of collagen leading to hypergranulation formation.  
 
Treatment 
The various causes of hypergranulation may be grouped under three headings,  
those that are inflammatory in nature (Type I), those that are related to an occluded 
wound environment (Type II) and those that are caused by a cellular imbalance of 
some kind (Type III). These three groupings provide the basis for different treatment 
pathways (Figure 1), however, before proceeding, it is important to rule out the 
possibility of malignancy in any hypergranulating wound as these two conditions 
may present with similar characteristics (Harris and Rolstad, 1994).  
This is done by: 
 taking a comprehensive patient and wound history 
 undertaking a clinical examination  
 ordering appropriate investigations where necessary e.g. tissue biopsy 
 referring for expert opinion e.g. dermatologist 
 
Treatment - Type 1  
Type 1 hypergranulation, which is inflammatory in nature, should be treated so as 
to resolve the inflammation through removal of the irritant or inflammatory factors.  
 Examine the wound bed carefully; it is sometimes possible to see and  
  remove dressing fibres and other  potential irritants. 
 
 Secure external medical devices such as gastrostomy tubes and central  
  lines red in such a way as to minimise friction around the wound site.  
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 Identify wound infection, a key cause of inflammation in wounds. Treat with  
 topical antimicrobials e.g. Actisorb®, Inadine®, Biatain Ag®. Select 
 secondary dressing, if required, on the basis of exudate levels. Avoid 
 occlusion. Treat systemic infection with oral or intravenous antibiotics as  
indicated. For further guidance on the management of wound infection refer 
to the EWMA Position Document ‘Management of Wound Infection’ (EWMA, 
2006). 
 
 If hypergranulation fails to respond to the above consider topical steroids;  
 these can effectively dampen the inflammatory  response and reduce  
 hypergranulation production (NICE, 2004). However, they may also impede  
 healing and products are often contra-indicated for use on open wounds  
 (Young, 1995). Licensed usage must therefore always be checked. One  
 potentially useful product is Haelan® tape (Typharm) which contains  
fludroxycortide, a moderately potent steroid. Haelan® tape is indicated as 
‘an adjunctive therapy for chronic, localised, recalcitrant dermatoses that 
may respond to topical corticosteroids’ (Mason, 2009). There is also an 
ointment version.  
 Use on hypergranulation tissue is at the discretion of the clinician and 
 application/duration should be according to the manufacturer’s  
 instructions. 
 
Treatment - Type II  
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Type II hypergranulation, developing as a result of an occluded wound 
environment, usually responds well to a change of dressing type.  
 Where the dressing in use is occlusive e.g. a hydrocolloid, a switch to a more  
 permeable product is indicated (Dunford, 1999). A film dressing e.g.  
 Tegaderm® or a polyurethane foam dressing with a high moisture vapour  
 transmission rate (MVTR) e.g. Lyofoam®, will improve gaseous exchange at  
 the wound interface and increase the rate of vapour loss through the back of  
 the dressing. Small studies by Harris (1991, cited in Harris and Rolstad,  
 1994) and by Harris and Rolstad (1994) found polyurethane dressings to be  
 of benefit when compared with treatments such as topical silver sulfadiazine  
 and hydrocolloids. 
 
 Where exudate levels are higher, a more absorbent dressing can be used  
 e.g. Mepilex®, Biatain®. The exact choice of dressing is dependant on  
 exudate levels however where these are high the possibility of infection  
 should always be eliminated first.  
 
 Secure dressings in such a way as to allow them to manage exudate and  
  vapour loss properly i.e. do not occlude dressings by applying layers of  
  adhesive film over them.    
 Where possible, apply moderate pressure to the wound using dressing pads,  
 crepe or tubular bandage over the area (taking care to avoid constricting   
 the blood supply). This may inhibit the further growth of hypergranulation  
 tissue.  
 Where bandaging is inadvisable, local pressure may be applied by  
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 alternative means such as re-positioning the patient to lie on the wound for  
short periods or by encouraging mobility to increase foot pressures  
 (taking care at all times not to cause the patient any harm as a consequence 
of applying pressure). 
 
Treatment - Type III  
Type III hypergranulation, appears to develop as a result of a cellular imbalance of 
some kind. It may be that the imbalance occurs as a result of an external factor and 
for this reason inflammation and occlusion should both be excluded as causes; 
however, if the trigger is internally located there may be little that can be done to 
reverse the cause. Therefore, until the causative mechanisms are better 
understood, effective management must rely on control of signs and symptoms 
using the same strategies as identified for Type I and Type II.   
 
The ‘wait and see’ option 
If malignancy and infection have been excluded a final option for all three 
hypergranulation types is to do nothing. Although an aberrant response, 
hypergranulation is normally transient and will often resolve itself as the wound 
contracts (Dunford, 1999). Adopting a wait and see policy may therefore carry fewer 
implications for the patient than some of the other options discussed.  
 
Unsuitable options 
Other treatment options cited in the literature include shave excision, curettage and 
surgery to mechanically debride the excess tissue and cautery, laser therapy, 
topical silver nitrate, phenols, copper sulphate and aluminium chloride to burn it 
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away (Harris and Rolstad, 1994; Dunford, 1999; Hawkins-Bradley and Walden, 
2002; Semchyshyn, 2009; Stevens et al, 2009). Mechanical removal of 
hypergranulation is argued against on the basis of causing a return to the 
inflammatory stage of healing during the re-creation of what is essentially a new 
wound, whilst caustic agents may cause pain (Harris and Rolstad, 1994), provoke a 
further inflammatory response (Nelsen, 1999) and in the case of silver nitrate, 
cause conditions such as methaemoglobinaemia and hyponatraemia to develop 
(Rollins, 2000; Dealey, 2005).  
 
Leaving the wound open is not advocated as wound bed exposure leads to cell 
death through tissue dessication and ultimately impacts on healing (Harris and  
Rolstad, 1994).  
 
Conclusion 
The literature indicates that a variety of factors contribute to the development of 
hypergranulation and that hypergranulation presents clinically in different ways.  
The recognition of contributory factors and clinical types facilitates decision making 
and, although the evidence based for treatment is limited, effective decisions can 
be made on the basis of identifying the likely cause of the problem. Finally, whilst 
several pathways for effective treatment exist it is important to remember that 
hypergranulation does not always impede healing and that sometimes adopting a 
‘wait and see’ approach is the best option of all. 
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Hypergranulation – clinical presentation 
Unhealthy appearance     Healthy appearance 
Exuberant tissue      Exuberant tissue  
Dark red - purple in colour     Red – pink in colour 
Wet / high exudate levels     Moist  
Bleeds readily       May bleed  
Friable (breaks down easily)     Not friable 
Spongy / oedematous       
Box 1. 
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Hypergranulation 
 
Identify Cause 
 
                   
Eliminate malignancy 
   
   
  Inflammation (Type I)     Occlusion (Type II)    Cellular imbalance (Type III) 
Infection?      Irritation / allergy?      
Topical antimicrobials  Remove cause e.g. dressing,   Apply high MVTR dressing*   Manage symptoms e.g. ↑exudate 
plus systemic antibiotics remnant fibre, wound debris,   Apply local pressure**   Apply high MVTR dressing*  
 if necessary   adhesive material, external device        Apply local pressure** 
Apply suitable secondary Apply high MVTR dressing*            
dressing.    Apply local pressure**        
    If no response after 7 days consider topical  
steroid e.g. Haelan®  
 
Consider ‘wait and see’ option for Type II and Type III when it is not possible to implement other management options or when hypergranulation is not impeding wound 
closure or patient rehabilitation. 
 
*Choose dressings with a high MVTR  e.g. film or polyurethane foam depending on exudate levels.  
**Local pressure in the form of bandaging must only be applied where arterial blood supply is sufficiently robust and where there are no contra-indications for doing so; it 
should be applied initially in the form of a firm crepe bandage. It is preferable to try a high MVTR dressing first before applying bandages as they may compromise the MVTR 
of the dressing  
 
Indicators of infection: High exudate levels, malodour, wound bed discolouration, cellulitus, bleeding, delayed healing    Figure 1 
